The gut microbiome and cognition in Parkinson’s disease: a systematic review

References

• Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci. 2002;3(12):932–942.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Brundin P. Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Mov Disord. 2013;28(1):31–40.
   PubMed Web of Science ®Google Scholar
• Mahul-Mellier A-L, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020;117(9):4971–4982.
   PubMed Web of Science ®Google Scholar
• Kim S, Kwon S-H, Kam T-I, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103(4):627–641.
   PubMed Web of Science ®Google Scholar
• Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(10):3005–3014.
   PubMedGoogle Scholar
• Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, et al. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol. 2014;184(4):966–975.
   PubMed Web of Science ®Google Scholar
• Lin C-H, Yang S-Y, Horng H-E, Yang C-C, Chieh J-J, Chen H-H, et al. Plasma α-synuclein predicts cognitive decline in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(10):818–824.
   PubMed Web of Science ®Google Scholar
• Henderson MX, Trojanowski JQ, Lee VMY. α-synuclein pathology in Parkinson’s disease and related α-synucleinopathies. Neurosci Lett. 2019;709:134316.
   PubMed Web of Science ®Google Scholar
• Bu J, Liu J, Liu K, Wang Z. Diagnostic utility of gut α-synuclein in Parkinson’s disease: a systematic review and meta-analysis. Behav Brain Res. 2019;364:340–347.
   PubMed Web of Science ®Google Scholar
• Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016;79(6):940–949.
   PubMed Web of Science ®Google Scholar
• Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110(5):517–536.
   PubMed Web of Science ®Google Scholar
• Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinsons Dis. 2017;3(1):3–9.
   PubMedGoogle Scholar
• Gorecki AM, Dunlop SA, Rodger J, Anderton RS. The gut-brain axis and gut inflammation in Parkinson’s disease: stopping neurodegeneration at the toll gate. Expert Opin Ther Targets. 2020;24(7):601–604.
   PubMed Web of Science ®Google Scholar
• Fan T-S, Liu SC-H, Wu R-M. Alpha-synuclein and cognitive decline in Parkinson disease. Life (Basel). 2021;11:1239.
   PubMed Web of Science ®Google Scholar
• Jones JD, Rahmani E, Garcia E, Jacobs JP. Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson’s disease. Parkinsonism Relat Disord. 2020;72:7–12.
   PubMed Web of Science ®Google Scholar
• Manderino L, Carroll I, Azcarate-Peril MA, Rochette A, Heinberg L, Peat C, et al. Preliminary evidence for an association between the composition of the gut microbiome and cognitive function in neurologically healthy older adults. J Int Neuropsychol Soc. 2017;23(8):700–705.
   PubMed Web of Science ®Google Scholar
• Goya ME, Xue F, Sampedro-Torres-Quevedo C, Arnaouteli S, Riquelme-Dominguez L, Romanowski A, et al. Probiotic Bacillus subtilis protects against α-synuclein aggregation in C. elegans. Cell Rep. 2020;30(2):367–380.
   PubMed Web of Science ®Google Scholar
• Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167(6):1469–1480.
   PubMed Web of Science ®Google Scholar
• Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, et al. Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(3):1031–1035.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-Sponsored Revision of the unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170.
   PubMed Web of Science ®Google Scholar
• Unger MM, Spiegel J, Dillmann K-U, Grundmann D, Philippeit H, Bürmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72.
   PubMed Web of Science ®Google Scholar
• Kenna JE, Chua EG, Bakeberg M, Tay A, McGregor S, Gorecki A, et al. Changes in the gut microbiome and predicted functional metabolic effects in an Australian Parkinson’s disease cohort. Front Neurosci. 2021;15:756951.
   PubMed Web of Science ®Google Scholar
• Nuzum ND, Loughman A, Szymlek-Gay EA, Hendy A, Teo W-P, Macpherson H. Gut microbiota differences between healthy older adults and individuals with Parkinson’s disease: a systematic review. Neurosci Biobehav Rev. 2020;112:227–241.
   PubMed Web of Science ®Google Scholar
• Toh TS, Chong CW, Lim S-Y, Bowman J, Cirstea M, Lin C-H, et al. Gut microbiome in Parkinson’s disease: new insights from meta-analysis. Parkinsonism Relat Disord. 2022;94:1–9.
   PubMed Web of Science ®Google Scholar
• Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease. Brain Behav Immun. 2018;70:194–202.
   PubMed Web of Science ®Google Scholar
• Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, et al. Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov Disord. 2019;34(3):396–405.
   PubMed Web of Science ®Google Scholar
• Ren T, Gao Y, Qiu Y, Jiang S, Zhang Q, Zhang J, et al. Gut microbiota altered in mild cognitive impairment compared with normal cognition in sporadic Parkinson’s disease. Front Neurol. 2020;11:137.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Kmet L, Lee RC, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta (CA): Alberta Heritage Foundation for Medical Research; 2004.
   Google Scholar
• Lee L, Packer TL, Tang SH, Girdler S. Self-management education programs for age-related macular degeneration: a systematic review. Australas J Ageing. 2008;27(4):170–176.
   PubMed Web of Science ®Google Scholar
• Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, et al. The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord. 2018;33(1):88–98.
   PubMed Web of Science ®Google Scholar
• Cilia R, Piatti M, Cereda E, Bolliri C, Caronni S, Ferri V, et al. Does gut microbiota influence the course of Parkinson’s disease? A 3-year prospective exploratory study in de novo patients. J Parkinsons Dis. 2021;11(1):159–170.
   PubMedGoogle Scholar
• Tan AH, Chong CW, Lim SY, Yap IKS, Teh CSJ, Loke MF, et al. Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann Neurol. 2021;89(3):546–559.
   PubMed Web of Science ®Google Scholar
• Biddle A, Stewart L, Blanchard J, Leschine S. Untangling the genetic basis of fibrolytic specialization by Lachnospiraceae and Ruminococcaceae in diverse gut communities. Diversity. 2013;5(3):627–640.
   Google Scholar
• Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–237.
   PubMed Web of Science ®Google Scholar
• Liu H, Hou C, Li N, Zhang X, Zhang G, Yang F, et al. Microbial and metabolic alterations in gut microbiota of sows during pregnancy and lactation. FASEB J. 2019;33(3):4490–4501.
   PubMed Web of Science ®Google Scholar
• Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The controversial role of human gut lachnospiraceae. Microorganisms. 2020;8(4):573.
   PubMed Web of Science ®Google Scholar
• Nishiwaki H, Ito M, Ishida T, Hamaguchi T, Maeda T, Kashihara K, et al. Meta-analysis of gut dysbiosis in Parkinson’s disease. Mov Disord. 2020;35(9):1626–1635.
   PubMed Web of Science ®Google Scholar
• Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease. Mol Neurodegener. 2021;16(1):6.
   PubMed Web of Science ®Google Scholar
• Vinolo MAR, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3(10):858–876.
   PubMed Web of Science ®Google Scholar
• Gill PA, Zelm MC, Muir JG, Gibson PR. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment Pharmacol Ther. 2018;48(1):15–34.
   PubMed Web of Science ®Google Scholar
• Carretta MD, Quiroga J, López R, Hidalgo MA, Burgos RA. Participation of short-chain fatty acids and their receptors in gut inflammation and colon cancer. Front Physiol. 2021;12:662739.
   PubMed Web of Science ®Google Scholar
• Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020;11:25.
   PubMed Web of Science ®Google Scholar
• Lema TC, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P. Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease – is there a link? Mol Neurobiol. 2013;47(2):561.
   PubMedGoogle Scholar
• Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph Timon E, Reider Simon J, et al. Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. Cell Host Microbe. 2016;19(4):455–469.
   PubMed Web of Science ®Google Scholar
• Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol. 2020;11:906.
   PubMed Web of Science ®Google Scholar
• Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–1745.
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349–356.
   PubMed Web of Science ®Google Scholar
• Lawrence BJ, Gasson N, Loftus AM. Prevalence and subtypes of mild cognitive impairment in Parkinson’s disease. Sci Rep. 2016;6(1):33929.
   PubMedGoogle Scholar
• Boertien JM, Pereira PAB, Aho VTE, Scheperjans F. Increasing comparability and utility of gut microbiome studies in Parkinson’s disease: a systematic review. J Parkinsons Dis. 2019;9(s2):S297–S312.
   PubMedGoogle Scholar